By Kathryn Calkins
& Mike Ward
Staff Writers

OXFORD - Transgene's successful bid to have its shares on both NASDAQ and the Nouveau Marche has confirmed that the dual listing route is still open to European bioscience companies, and caps a small budding of biotech IPO and follow-on offerings that is springing from Europe's domestic stock exchanges.